-
Protocol
Assessing the Efficacy of Immune Checkpoint Inhibitors in Preclinical Tumor Models
The identification of novel immune-related targets that can reactivate or enhance antitumor immunity is a very active field of cancer research. In this context, syngeneic tumor models are often used during the...
-
Article
Publisher Correction: The adenosine pathway in immuno-oncology
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Article
The adenosine pathway in immuno-oncology
Cancer immunotherapy based on immune-checkpoint inhibition or adoptive cell therapy has revolutionized cancer care. Nevertheless, a large proportion of patients do not benefit from such treatments. Over the pa...
-
Article
miR-216 and miR-217 expression is reduced in transgenic mouse models of pancreatic adenocarcinoma, knockout of miR-216/miR-217 host gene is embryonic lethal
Mice harboring a G12D activating Kras mutation are among the most heavily studied models in the field of pancreatic adenocarcinoma (PDAC) research. miRNAs are differentially expressed in PDAC from patients and...
-
Protocol
Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies
Immune checkpoint inhibitors (ICI) are a new class of drugs characterized by their ability to enhance antitumor immune responses through the blockade of critical cell surface receptors involved in the maintena...
